Oncology

NICE issues final guidance on the use of cetuximab for the treatment of head and neck cancer

The National Institute for Health and Clinical Excellence (NICE) has today (24 June) published guidance on cetuximab for the treatment of recurrent and/or metastatic (where the cancer has spread) squamous cell cancer of the head and neck.
Read more

 http://www.nice.org.uk/newsroom/pressreleases/press_releases...

National Institute for Health and Clinical Excellence